References
- Seppälä M. Oncodevelopmental antigens in gynecologic cancer. Oncodevelopmental markers. Biologic, diagnostic, and monitoring aspects, W H Fishman. Academic Press, New York 1983; 373–93
- Bast R C, Jr, Klug T L, St. John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309: 883–7
- Bast R C, Jr, Klug T L, Schaetzl E, Lavin P, Niloff J M, Greber T F, Zurawski V R, Jr, Knapp R C. Monitoring human ovarian carcinoma with a combination of CA 125, CA 19–9 and carcinoembryonic antigen. Am J Obstet Gynecol 1984; 149: 553–9
- Canney P A, Moore M, Wilkinson P M, James R D. Ovarian cancer antigen CA 125. A prospective clinical assessment of its role as a tumour marker. Br J Cancer 1986; 50: 765–9
- Kivinen S, Kuoppala T, Leppilampi M, Vuori J, Kauppila A. Tumor-associated antigen Ca 125 before and during the treatment of ovarian carcinoma. Obstet Gynecol 1986; 67: 468–72
- International Federation of Gynecology and Obstetrics. Classification and staging of malignant tumors in the female pelvis. J Int Fed Gynecol Obstet 1965; 3: 204–10
- Miller A B, Hoogstraten B, Staquet M., et al. Reporting results of cancer treatment. Cancer 1981; 47: 207–14
- Malkasian G D, Jr, Podratz K C, Stanhope C R, Ritts R E, Zurawski V R, Jr. CA 125 in gynecologic practice. Am J Obstet Gynecol 1986; 155: 515–8
- Klug T L, Bast R C, Jr, Niloff J M, Knapp R C, Zurawski V R, Jr. Monoclonal antibody radioimmunometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res 1984; 44: 48–53
- Halila H, Stenman U-H, Seppälä M. Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy. Cancer 1986; 57: 1327–9
- Niloff J M, Bast R C, Jr, Schaetzl E M, Knapp R C. Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. Am J Obstet Gynecol 1985; 151: 981–6
- Berek J S, Knapp R C, Malkasian G D, Lavin F T, Whitney C, Niloff J M, Bast R C, Jr. CA 125 serum levels correlated with second-look operations among ovarian cancer patients. Obstet Gynecol 1986; 67: 685–9
- Atack D B, Nisker J A, Allen H H, Tustanoff E R, Levin L. CA 125 surveillance and second-look laparotomy in ovarian carcinoma. Am J Obstet Gynecol 1986; 154: 287–9
- Huhtala M-L, Kahanpää K, Seppälä M, Halila H, Stenman U-H. Increased excretion of a tumor-associated trypsin inhibitor (TATI) in urine of patients with gynecological malignancy. Int J Cancer 1983; 31: 711–3
- Halila H, Lehtovirta P, Stenman U-H. Tumor-associated trypsin inhibitor (TATI) in ovarian cancer. Br J Cancer, in press